2023
DOI: 10.1007/s13555-023-00937-9
|View full text |Cite
|
Sign up to set email alerts
|

Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database

Abstract: Introduction Alopecia areata (AA) is an autoimmune disease with an underlying immuno-inflammatory pathogenesis. Treatments can include systemic corticosteroids and immunomodulators (such as Janus kinase inhibitors); these medications may be associated with a risk of some adverse events. However, large-scale observational studies of baseline incidence rates (IRs) of infection, cardiovascular disease, malignancy, and thromboembolism in US patients with AA, including those with alopecia totalis or al… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
5
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 23 publications
0
5
0
Order By: Relevance
“…The IRs of serious infections were low across the ALLEGRO program; in this analysis, the IR was 0.66/100 PY in the ritlecitinib 50-mg group. In a real-world US claims-based study, the IR for serious infections was 1.85/100 PY (95% CI 1.65, 2.08) in patients with AA [ 23 ].…”
Section: Discussionmentioning
confidence: 99%
See 4 more Smart Citations
“…The IRs of serious infections were low across the ALLEGRO program; in this analysis, the IR was 0.66/100 PY in the ritlecitinib 50-mg group. In a real-world US claims-based study, the IR for serious infections was 1.85/100 PY (95% CI 1.65, 2.08) in patients with AA [ 23 ].…”
Section: Discussionmentioning
confidence: 99%
“…A dose-related increase in HZ infections was observed with ritlecitinib, which is consistent with previous reports for other immunomodulators, including JAK inhibitors [ 11 , 13 ]. In the ritlecitinib 50-mg group of the all exposure pool of this analysis, the IR for HZ was 0.99/100 PY (95% CI 0.60, 1.55); in the US-based cohort study in patients with AA, the IR was 0.78/100 PY (95% CI 0.65, 0.93) [ 23 ]. Rates were lower in the all-exposure pool than in the placebo-controlled pool, suggesting no increased risk with longer ritlecitinib treatment.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations